98%
921
2 minutes
20
Background: Prostate cancer (PCa) remains a leading global malignancy, yet current diagnostic reliance on prostate-specific antigen (PSA) testing is limited by suboptimal sensitivity and specificity for early-stage detection. The present study aims to establish an effective high-throughput screening technique for accurate PCa diagnosis.
Methods: A large-scale cohort of 28,892 subjects was considered for inclusion in this study, and 1133 volunteers were finally selected, including 600 healthy controls, 160 patients diagnosed with other diseases of urinary system, 89 patients diagnosed with benign prostate hyperplasia (BPH), and 284 PCa patients. Discovery and internal validation phases of diagnostic models were conducted through machine learning of urine metabolic fingerprints obtained by laser desorption/ionization mass spectrometry (LDI-MS). Furthermore, the developed diagnostic model was verified in an external validation cohort.
Results: In retrospective cohort, the stepwise binary classification model achieved satisfactory diagnostic performance with areas under curves (AUCs) of 0.9599–0.9957 in the discovery ( = 567) and internal validation dataset ( = 284). In the external validation cohort ( = 282), AUC values from the ROC curves that differentiate Non-PD from PD, BPH from PCa, and HC from UD were 0.9815, 0.9705, and 0.9980, respectively. More than 95% significant PCa patients in the gray area (3 < tPSA < 10 ng/mL) were successfully identified from BPH subjects. Notably, four metabolite-related candidate genes were identified in this work, including , , and .
Conclusions: This study demonstrated the clinical potential of an LDI-MS-based non-invasive urine biopsy for early prostate cancer detection, particularly in improving diagnostic accuracy for patients with tPSA levels in the gray zone (3–10 ng/mL).
Supplementary Information: The online version contains supplementary material available at 10.1186/s40364-025-00804-z.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12239324 | PMC |
http://dx.doi.org/10.1186/s40364-025-00804-z | DOI Listing |
JCO Clin Cancer Inform
September 2025
USC Institute of Urology and Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Purpose: To evaluate a generative artificial intelligence (GAI) framework for creating readable lay abstracts and summaries (LASs) of urologic oncology research, while maintaining accuracy, completeness, and clarity, for the purpose of assessing their comprehension and perception among patients and caregivers.
Methods: Forty original abstracts (OAs) on prostate, bladder, kidney, and testis cancers from leading journals were selected. LASs were generated using a free GAI tool, with three versions per abstract for consistency.
JCO Precis Oncol
September 2025
Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA.
Clin Nucl Med
September 2025
Department of Radiology and Nuclear Medicine, Comprehensive Cancer Care and Research Center (SQCCCRC), University Medical City, Muscat, Oman.
PSMA-targeted radioligand therapies with 177Lu-PSMA-617 have shown promising response rates with favorable toxicity in patients with metastasized castration-resistant prostate cancer. We report a case of a 72-year-old man with metastatic castration-resistant prostate cancer having comorbidities of DM, HTN, and end-stage renal disease (ESRD) on regular hemodialysis. The patient received 2 doses of 7.
View Article and Find Full Text PDFJ Med Chem
September 2025
State Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China.
Resistance-conferring mutations in the androgen receptor (AR) ligand-binding pocket (LBP) compromise the effectiveness of clinically approved orthosteric AR antagonists. Targeting the dimerization interface pocket (DIP) of AR presents a promising therapeutic approach. In this study, we report the design and optimization of -(thiazol-2-yl) furanamide derivatives as novel AR DIP antagonists, among which was the most promising candidate.
View Article and Find Full Text PDFJAMA
September 2025
Division of Surgery and Interventional Science, UCL, London, United Kingdom.
Importance: Multiparametric magnetic resonance imaging (MRI), with or without prostate biopsy, has become the standard of care for diagnosing clinically significant prostate cancer. Resource capacity limits widespread adoption. Biparametric MRI, which omits the gadolinium contrast sequence, is a shorter and cheaper alternative offering time-saving capacity gains for health systems globally.
View Article and Find Full Text PDF